Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Lynn Malec, Beatrice Nolan, Anthony K C Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Blood (2024) 144 (Supplement 1): 5495.

https://doi.org/10.1182/blood-2024-206915

Published: 2024

Journal Articles

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children with Severe Hemophilia A in the XTEND-Kids Phase 3 Study

Lynn Malec, Amy Dunn, Manuel Carcao, Bulent Zulfikar, Ruben Berrueco, Simon Brown, Umer Khan, Sriya Gunawardena, Graham Neill, Lydia Abad-Franch, Linda Bystrická, Elena Santagostino, Sophie Susen

Blood (2023) 142 (Supplement 1): 3993.

https://doi.org/10.1182/blood-2023-188739

Published: 2023

Journal Articles

Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A

Flora Peyvandi, Cristina Tarango, Mindy Simpson, Manuela Albisetti, Maria Teresa Álvarez-Roman, Anthony KC Chan, Julie Curtin, Linda Bystrická, Elena Santagostino, Ekaterina Gresko, Sriya Gunawardena, Chandravathi Vage, Nancy Wong

Blood (2023) 142 (Supplement 1): 506.

https://doi.org/10.1182/blood-2023-188649

Published: 2023

Journal Articles

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Menapace, Ana Paula Marques, Sriya Gunawardena, Marie Scully

Blood (2022) 140 (Supplement 1): 5651–5653.

https://doi.org/10.1182/blood-2022-156306

Published: 2022

Journal Articles

A Phase 3 Study to Evaluate the Efficacy and Safety of Caplacizumab without First-Line Therapeutic Plasma Exchange in Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Sriya Gunawardena, Angela Hu, Laurel A. Menapace, Hikaru Okada, Beverly Accomando, Julie Lin

Blood (2022) 140 (Supplement 1): 2770–2771.

https://doi.org/10.1182/blood-2022-156304

Published: 2022

Journal Articles

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results

Christoph Königs, Margareth C. Ozelo, Amy Dunn, Roshni Kulkarni, Beatrice Nolan, Simon A. Brown, Michele Schiavulli, Sriya Gunawardena, Sutirtha Mukhopadhyay, Deepthi Jayawardene, Bent Winding, Manuel Carcao

Blood (2022) 139 (26): 3699–3707.

https://doi.org/10.1182/blood.2021013563

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga Strebel, Jessica Minkue Mi Edou, Rui de Passos Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

Blood (2021) 138 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2021-148839

Published: 2021

Journal Articles

Real-World Utilization and Safety of Daratumumab Rapid Infusion Administered in a Community Setting: A Retrospective Observational Study

Lucio Gordon, MD, Melody Chang, RPh, MBA, Marie-Hélène Lafeuille, MA, Hela Romdhani, PhD, Faud Paramasivam, Xinmei Zhu, PhD, Sriya Gunawardena, Eric M Maiese, PhD

Blood (2019) 134 (Supplement_1): 5575.

https://doi.org/10.1182/blood-2019-128515

Published: 2019

Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD

Blood (2019) 134 (Supplement_1): 863.

https://doi.org/10.1182/blood-2019-122497

Published: 2019

Journal Articles

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, William I. Bensinger, MD, John M Burke, MD, Sriya Gunawardena, MD, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, PhD, Anil Londhe, PhD, Ming Qi, Jon Ukropec, Thomas Lin, Robert M. Rifkin, MD

Blood (2017) 130 (Supplement 1): 1839.

https://doi.org/10.1182/blood.V130.Suppl_1.1839.1839

Published: 2017

Journal Articles

Validation Study Of The Composite Score To Identify Von Willebrand Disease in Children

Lynn M. Malec, MD, Charity G. Moore, MSPH, PhD, Carolyn M. Bennett, MD, MS, Donald L Yee, MD, Bryce A. Kerlin, MD, Char Witmer, MD, Sriya Gunawardena, MD, Roshni Kulkarni, MD, Sweta Gupta, MBBS, MD, Peter A. Kouides, MD, Deborah Brown, Heather L. Bujnicki, MD, Margaret V. Ragni, MD, MPH

Blood (2013) 122 (21): 2356.

https://doi.org/10.1182/blood.V122.21.2356.2356

Published: 2013

Journal Articles

Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities.

Steven J. Ambrusko, MD, Sriya Gunawardena, MBBS, Allison Sakara, CRNP, Beth Windsor, CRNP, Lizabeth Lanford, MD, Peter Michelson, MD, Lakshmanan Krishnamurti, MD

Blood (2005) 106 (11): 3791.

https://doi.org/10.1182/blood.V106.11.3791.3791

Published: 2005

NARROW

Clinical Outcomes over 2 Years of Once-Weekly Efanesoctocog Alfa Treatment in Children with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children with Severe Hemophilia A in the XTEND-Kids Phase 3 Study

Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

A Phase 3 Study to Evaluate the Efficacy and Safety of Caplacizumab without First-Line Therapeutic Plasma Exchange in Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Real-World Utilization and Safety of Daratumumab Rapid Infusion Administered in a Community Setting: A Retrospective Observational Study

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Validation Study Of The Composite Score To Identify Von Willebrand Disease in Children

Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only